Lodaxaprine is a chemically original compound which possesses the pharmacological properties of a potent, p.o. active anticonvulsant. In mice, lodaxaprine antagonized electroconvulsive shock and chemically induced seizures with an overall potency comparable to that of carbamazepine. In naturally photosensitive Senegalese Papio-papio baboons lodaxaprine antagonized myoclonus and cortical paroxysmal discharges. In this model lodaxaprine was approximately one-fourth as potent as phenobarbital, twice as potent as carbamazepine and 6 times more potent than sodium valproate. Lodaxaprine had been in phase II clinical trial for the treatment of epilepsy. However, this development was discontinued.

Benzobarbital (under the brand name Benzona), a barbiturate derivative developed in Russia that is used to treat convulsive forms of epilepsy, newborn hemolytic disease, and insomnia.

Bentipimine was developed as an anticholinergic agent.

Nafoxadol is an analgesic agent.

Mobenzoxamine is gastro-intestinal function modulator, that enhanced gastric emptying. In preclinical models clathrate compound of mobenzoxamine with beta-cyclodextrin showed a clear amelioration of the delayed gastric emptying induced by Barium chloride. On isolated guinea pig ileum, Mobenzoxamine inhibited contractions induced by various agonists equally to or more potently than trimebutine or papaverine.

Metbufen is a non-steroid anti-inflammatory drug.

Guaimesal was studied for the treatment of exacerbated chronic bronchitis

Ifoxetine was developed as an unusual drug that specifically and selectively blocks the 5-HT reuptake in the brain without affecting the 5-HT uptake processes in the periphery (blood platelets). The drug was undergoing phase II clinical trials for the treatment of depression; however, the study was suspended.